CXCL12-PLGA/Pluronic Nanoparticle Internalization Abrogates CXCR4-Mediated Cell Migration.
cancer
cell-migration
chemokine-receptor
chemokines
immune cells
nanoparticles
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
20 Nov 2020
20 Nov 2020
Historique:
received:
10
10
2020
revised:
18
11
2020
accepted:
19
11
2020
entrez:
25
11
2020
pubmed:
26
11
2020
medline:
26
11
2020
Statut:
epublish
Résumé
Chemokine-induced chemotaxis mediates physiological and pathological immune cell trafficking, as well as several processes involving cell migration. Among them, the role of CXCL12/CXCR4 signaling in cancer and metastasis is well known, and CXCR4 has been often targeted with small molecule-antagonists or short CXCL12-derived peptides to limit the pathological processes of cell migration and invasion. To reduce CXCR4-mediated chemotaxis, we adopted a different approach. We manufactured poly(lactic acid-co-glycolic acid) (PLGA)/Pluronic F127 nanoparticles through microfluidics-assisted nanoprecipitation and functionalized them with streptavidin to docking a biotinylated CXCL12 to be exposed on the nanoparticle surface. Our results show that CXCL12-decorated nanoparticles are non-toxic and do not induce inflammatory cytokine release in THP-1 monocytes cultured in fetal bovine and human serum-supplemented media. The cell internalization of our chemokine receptor-targeting particles increases in accordance with CXCR4 expression in FBS/medium. We demonstrated that CXCL12-decorated nanoparticles do not induce cell migration on their own, but their pre-incubation with THP-1 significantly decreases CXCR4
Identifiants
pubmed: 33233846
pii: nano10112304
doi: 10.3390/nano10112304
pmc: PMC7699919
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nanomedicine. 2016 Oct;12(7):1987-1996
pubmed: 27085904
Histol Histopathol. 2014 Dec;29(12):1539-46
pubmed: 24879309
Annu Rev Immunol. 2014;32:659-702
pubmed: 24655300
Biomaterials. 2014 May;35(15):4525-4535
pubmed: 24612919
Gen Comp Endocrinol. 2018 Mar 1;258:4-14
pubmed: 28694053
Theranostics. 2020 Apr 6;10(12):5169-5180
pubmed: 32373205
Leukemia. 2006 Nov;20(11):1915-24
pubmed: 16900209
FEMS Microbiol Lett. 2004 Dec 1;241(1):1-12
pubmed: 15556703
Curr Drug Targets. 2012 Feb;13(2):166-72
pubmed: 22204316
J Leukoc Biol. 2016 Jun;99(6):993-1007
pubmed: 26819318
J Leukoc Biol. 2016 Jun;99(6):869-82
pubmed: 26729814
Antivir Chem Chemother. 2019 Jan-Dec;27:2040206619829382
pubmed: 30776910
Semin Cancer Biol. 2004 Jun;14(3):171-9
pubmed: 15246052
Sci Rep. 2020 Sep 2;10(1):14505
pubmed: 32879363
Rev Neurosci. 2016 Jan;27(1):83-92
pubmed: 26353174
Tumour Biol. 2016 Jul;37(7):8515-28
pubmed: 27079871
J Gene Med. 2009 Sep;11(9):772-81
pubmed: 19562713
Cells. 2019 Dec 24;9(1):
pubmed: 31878341
Acta Biomater. 2019 Nov;99:426-432
pubmed: 31494293
Colloids Surf B Biointerfaces. 2015 Sep 1;133:43-50
pubmed: 26070050
Eur J Immunol. 2001 Nov;31(11):3291-7
pubmed: 11745346
Immunity. 1999 Apr;10(4):463-71
pubmed: 10229189
Nature. 2019 Jan;565(7739):318-323
pubmed: 30542158
Front Immunol. 2020 Jan 31;11:94
pubmed: 32076421
J Hematol Oncol. 2020 Apr 15;13(1):36
pubmed: 32295630
Small. 2018 Jun;14(26):e1800665
pubmed: 29845742
J Virol. 2003 Jan;77(2):931-42
pubmed: 12502809
Acta Haematol. 2019;142(2):64-70
pubmed: 31096215
EMBO J. 1997 Dec 1;16(23):6996-7007
pubmed: 9384579
J Neuroimmune Pharmacol. 2012 Dec;7(4):820-34
pubmed: 22270883
J Virol. 1999 Sep;73(9):7489-96
pubmed: 10438838
Cancer Med. 2017 Jun;6(6):1424-1436
pubmed: 28544785
Curr Pharmacol Rep. 2016 Feb;2(1):1-10
pubmed: 27088072
Immunity. 2012 May 25;36(5):705-16
pubmed: 22633458
Clin Cancer Res. 2010 Jun 1;16(11):2927-31
pubmed: 20484021
Future Oncol. 2014 Apr;10(5):749-59
pubmed: 24799056
Int J Pharm. 2017 Dec 20;534(1-2):97-107
pubmed: 29017804
J Neurovirol. 2006 Jun;12(3):211-8
pubmed: 16877302
PLoS One. 2012;7(4):e34038
pubmed: 22485156
Blood. 2011 Jan 13;117(2):451-8
pubmed: 20944068
EMBO Mol Med. 2018 Oct;10(10):
pubmed: 30190334
FEBS J. 2018 Aug;285(16):2944-2971
pubmed: 29637711
Drug Des Devel Ther. 2015 Aug 28;9:4953-64
pubmed: 26356032
Int J Nanomedicine. 2012;7:4533-44
pubmed: 22923991
Haematologica. 2020 Mar;105(3):741-753
pubmed: 31248974
PLoS One. 2014 Jan 31;9(1):e87394
pubmed: 24498095
ACS Appl Mater Interfaces. 2019 Jul 31;11(30):26607-26618
pubmed: 31282644
Nat Rev Immunol. 2011 Aug 25;11(9):597-606
pubmed: 21866172
J Pathol. 2012 Jan;226(2):148-57
pubmed: 21989643
J Immunol. 2004 Dec 15;173(12):7150-60
pubmed: 15585836
Nat Immunol. 2019 Oct;20(10):1393-1403
pubmed: 31477919
Gene. 2018 Jan 30;641:105-110
pubmed: 29017963
Int J Pharm. 2016 Dec 30;515(1-2):431-440
pubmed: 27789364
Nanotechnology. 2019 Mar 15;30(11):115101
pubmed: 30561375